Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Adeel Ahmad

Dermatopathology Beckley, WV Medical Doctor

NPI 1578717997 CMS profile 71946

94 Brookshire Ln, Beckley, WV 25801

Open in the dashboard

General payments

$1,239

59 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adeel Ahmad of Beckley, WV is reported in the CMS Open Payments database as having received $1,239 across 59 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Dermatopathology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $34 2
2024 General $95 1
2023 General $138 2
2022 General $43 3
2021 General $325 18
2020 General $362 22
2019 General $241 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adeel Ahmad
  • Dermatopathology median
  • Middle half of Dermatopathology
  • National median

In program year 2025, general payments to Adeel Ahmad were reported at $34. Among 238 Dermatopathology profiles paid that year, the median was $251 and the middle half received between $93 and $1,140.

Show as a table
Year Adeel Ahmad Dermatopathology median Middle half National median
2019 $241 $295 $101–$807 $163
2020 $362 $154 $53–$443 $114
2021 $325 $226 $66–$781 $132
2022 $43 $258 $76–$906 $149
2023 $138 $303 $93–$1,129 $160
2024 $95 $324 $101–$1,343 $164
2025 $34 $251 $93–$1,140 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $437 25 payments
  2. Sun Pharmaceutical Industries Inc. $192 10 payments
  3. Lilly USA, LLC $116 6 payments
  4. Heron Therapeutics, Inc. $112 1 payment
  5. Kerecis Limited $95 1 payment
  6. Janssen Biotech, Inc. $85 6 payments
  7. Regeneron Healthcare Solutions, Inc. $67 2 payments
  8. DUSA Pharmaceuticals, Inc. $36 2 payments
  9. CSL Behring $26 1 payment
  10. Calliditas Therapeutics US Inc. $18 1 payment
  11. Other $57 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,239 59 payments
Products named General payments · program years 2019–2025
  1. SKYRIZI $312 17 payments
  2. HUMIRA $257 15 payments
  3. ILUMYA $137 8 payments
  4. TALTZ $116 6 payments
  5. ZYNRELEF $112 1 payment
  6. Kerecis Omega3 SurgiClose $95 1 payment
  7. Kerecis Omega3 Marigen Wound Care $95 1 payment
  8. Kerecis Omega3 Marigen Wound Care $95 1 payment
  9. Kerecis Omega3 Marigen Wound Care $95 1 payment
  10. Kerecis Omega3 Marigen Wound Care $95 1 payment
  11. Other $691 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$573,995

Medicare's payments for the services billed

Medicare patients

4,484

Average age 75

Services billed

9,379

2,167 women, 2,317 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 44%
Ischemic heart disease 28%
Diabetes 24%
Chronic kidney disease 21%
Atrial fibrillation 19%
Cancer 17%
Depression 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

59 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatopathology in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record